Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
Keyword(s):
2012 ◽
Vol 164
(4)
◽
pp. 600-606.e1
◽